1. Home
  2. INTS vs DLXY Comparison

INTS vs DLXY Comparison

Compare INTS & DLXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.51

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

DLXY

Delixy Holdings Limited Ordinary Shares

N/A

Current Price

$1.00

Market Cap

13.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
INTS
DLXY
Founded
2012
2007
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0M
13.9M
IPO Year
2023
2025

Fundamental Metrics

Financial Performance
Metric
INTS
DLXY
Price
$0.51
$1.00
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.33
N/A
AVG Volume (30 Days)
4.1M
31.1K
Earning Date
11-06-2025
12-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
N/A
$314,916,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$14.42
Revenue Growth
N/A
8.90
52 Week Low
$0.19
$0.64
52 Week High
$3.17
$7.16

Technical Indicators

Market Signals
Indicator
INTS
DLXY
Relative Strength Index (RSI) 57.01 N/A
Support Level $0.35 N/A
Resistance Level $0.42 N/A
Average True Range (ATR) 0.05 0.00
MACD 0.00 0.00
Stochastic Oscillator 88.83 0.00

Price Performance

Historical Comparison
INTS
DLXY

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About DLXY Delixy Holdings Limited Ordinary Shares

Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.

Share on Social Networks: